LiraglutidevsRetatrutide
Liraglutide vs Retatrutide — independent comparison of uses, administration, pricing across providers, and key differences. Last reviewed April 21, 2026.
Quick Verdict
Based on clinical evidence and real patient data
A GLP-1 receptor agonist administered daily for chronic weight management. FDA-approved as Saxenda for obesity and as Victoza for type 2 diabetes. One of the first GLP-1 medications widely used for weight loss before semaglutide.
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Best choice depends on your insurance, budget, and treatment history.Take the quiz to get a personalized recommendation.
Liraglutide vs Retatrutide: At a Glance
Full comparison across all key factors.
| Factor | LiraglutideALLY PICK | Retatrutide |
|---|---|---|
| Category | weight-loss | weight-loss |
| Also Known As | Saxenda, Victoza | LY3437943 |
| Administration | Subcutaneous injection (daily) | Subcutaneous injection (weekly) |
| Prescription | Required | Required |
| Providers | 4 providers✓ Better | 3 providers |
| Common Uses |
|
|
Data sourced from FDA prescribing information and peer-reviewed clinical trials. Prices reflect telehealth platform costs as of April 21, 2026. See our methodology.
Pricing by Provider
2 providers offer both Liraglutide and Retatrutide.
| Provider | Liraglutide | Retatrutide | Consultation | Lab Testing |
|---|---|---|---|---|
 | $220/monthly | $450/monthly | Video Telehealth | Yes |
 | $250/monthly | $480/monthly | Video Telehealth | Yes |
 | $299/monthly | Not offered | Video Telehealth | Yes |
 | $200/monthly | Not offered | Video Telehealth | No |
 | Not offered | $550/monthly | Video Telehealth | Yes |
Key Differences
Liraglutide
More ProvidersA GLP-1 receptor agonist administered daily for chronic weight management. FDA-approved as Saxenda for obesity and as Victoza for type 2 diabetes. One of the first GLP-1 medications widely used for weight loss before semaglutide.
Retatrutide
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Which Is Right for You?
Choose Liraglutideif…
- You want a weight-loss medication
- You prefer subcutaneous injection (daily) administration
- You want more provider options (4 available)
- Your primary goal is weight loss
- Your primary goal is appetite suppression
Choose Retatrutideif…
- You want a weight-loss medication
- You prefer subcutaneous injection (weekly) administration
- 3 providers available on our platform
- Your primary goal is weight loss
- Your primary goal is metabolic health
Frequently Asked Questions
What is the difference between Liraglutide and Retatrutide?
Which is cheaper, Liraglutide or Retatrutide?
Can I switch from Liraglutide to Retatrutide?
Medical Disclaimer
This comparison is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary. The information presented reflects publicly available data and may not account for your specific health situation.
Related Guides
Generic Liraglutide (Saxenda Generic): The Budget GLP-1 Nobody's Talking About
Generic liraglutide from Teva is the first generic GLP-1 for weight loss. At ~$230/month, is it a viable budget alternative to semaglutide and orforglipron? Complete pricing and comparison guide.
Read guide →Read guide →Retatrutide: The Triple-Agonist GLP-1 That Could Change Everything
Complete guide to retatrutide — Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) with 28.7% weight loss in trials. Clinical data, how it compares, and when it might be available.
Read guide →Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?
No official pricing exists for retatrutide — it hasn't been FDA-approved. Based on Lilly's existing portfolio, expect a list price of $1,000-1,500/mo with LillyDirect pricing potentially reducing that to $299-449/mo. Here's what we know, what we can project, and how to prepare.
Read guide →